Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity

Approximately 12% of patients with acute myocardial infarction (AMI) experience a recurrent major adverse cardiovascular event within 1 year of their primary event, with most occurring within the first 90 days. Thus, there is a need for new therapeutic approaches that address this 90‐day post‐AMI hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kingwell, Bronwyn A., Nicholls, Stephen J., Velkoska, Elena, Didichenko, Svetlana A., Duffy, Danielle, Korjian, Serge, Gibson, C. Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Basic Science for Clinicians
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238469/
https://www.ncbi.nlm.nih.gov/pubmed/35411789
http://dx.doi.org/10.1161/JAHA.121.024754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238469/
https://www.ncbi.nlm.nih.gov/pubmed/35411789
http://dx.doi.org/10.1161/JAHA.121.024754

Ejemplares similares